{"entity":{"id":"nct01975701","kind":"trial","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","aka":[],"tldr":"A phase 2 trial of Infigratinib in Glioma & glioblastoma, run by Novartis Pharmaceuticals, completed.","summary":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM is a phase 2 interventional study registered as NCT01975701 by Novartis Pharmaceuticals, with 26 participants recorded, started 2013-12-09 and reaching its primary completion in 2018-10-03. Interventions recorded: BGJ398. Conditions recorded: Recurrent Glioblastoma or Other Glioma Subtypes.\n\nLinked to the drug Infigratinib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01975701","url":"https://clinicaltrials.gov/study/NCT01975701"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["infigratinib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01975701","phase":"2","setting":"A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma","sponsor":"Novartis Pharmaceuticals","started":"2013-12-09","startedType":"actual","yearReported":2019,"enrolled":26,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival","primary":true,"unit":"months","arms":[{"name":"BGJ398X","n":24,"value":1.7,"note":"95% CI 1.05 to 2.80; Figures from the ClinicalTrials.gov results section (first posted 2019-12-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01975701?tab=results"},{"endpoint":"Overall Survival","unit":"months","arms":[{"name":"BGJ398X","n":26,"value":6.74,"note":"95% CI 4.17 to 11.73; Figures from the ClinicalTrials.gov results section (first posted 2019-12-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01975701?tab=results"}]},"route":"/trials/nct01975701/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}